<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="163114">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01891396</url>
  </required_header>
  <id_info>
    <org_study_id>Cingal 13-01</org_study_id>
    <nct_id>NCT01891396</nct_id>
  </id_info>
  <brief_title>Cingal Study for Knee Osteoarthritis</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo Controlled, Multi-Center Study of a Single Injection Cross-Linked Sodium Hyaluronate Combined With Triamcinolone Hexacetonide (Cingal) to Provide Symptomatic Relief of Osteoarthritis of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anika Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Anika Therapeutics, Inc.</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
    <authority>Bulgaria: Bulgarian Drug Agency</authority>
    <authority>Czech Republic: State Institute for Drug Control</authority>
    <authority>Hungary: Scientific and Medical Research Council Ethics Committee</authority>
    <authority>Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if a single injection of Cingal into the knee provides
      safe relief of pain caused by osteoarthritis.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Score</measure>
    <time_frame>12 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from baseline in the WOMAC pain score.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">368</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single injection of 0.9% saline supplied as a 4 mL unit dose in a 5mL glass syringe</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hyaluronic Acid and TH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single injection of sodium hyaluronate with triamcinolone hexacetonide (TH) supplied as a 4 mL unit dose in a 5 mL glass syringe</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hyaluronic Acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single injection of sodium hyaluronate supplied as a 4 mL unit dose in a 5 mL glass syringe</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hyaluronic Acid and TH</intervention_name>
    <arm_group_label>Hyaluronic Acid and TH</arm_group_label>
    <other_name>Cingal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hyaluronic Acid</intervention_name>
    <arm_group_label>Hyaluronic Acid</arm_group_label>
    <other_name>Monovisc</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Saline placebo packaged to look identical to comparator syringes.</description>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is 40 - 75 years old with a Body Mass Index (BMI)â‰¤ 40 kg/m2

          -  Subject has Kellgren-Lawrence(K-L)severity grade I, II, or III in the index knee as
             determined by X-Ray. Contralateral knee: K-L severity grade 0, I, or II.

        Exclusion Criteria:

          -  Subject received an IA injection of Hyaluronic Acid (HA) and/or steroid in either
             knee within 6 months of signing the ICF.

          -  Subject had an arthroscopy of either knee within 3 months of signing the ICF.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laszlo Hangody, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Uzsoki Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Deakon Medicine Professional Corporation</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <zip>L6K 3T7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 3, 2014</lastchanged_date>
  <firstreceived_date>June 28, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Knee osteoarthritis</keyword>
  <keyword>Hyaluronic acid</keyword>
  <keyword>HA Injection</keyword>
  <keyword>Steroid Injection</keyword>
  <keyword>Knee injection</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hyaluronic Acid</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
